Literature DB >> 9246165

The use of the frequency-doubled Q-switched Nd:YAG laser in the treatment of small cutaneous vascular lesions.

D J Goldberg1, J Marcus.   

Abstract

BACKGROUND AND
DESIGN: The frequency-doubled Q-switched, neodymium:yttrium-aluminum-garnet (FD QSNd:YAG) laser has proven to be safe and effective in treating cutaneous pigmented lesions and tattoos. The observance of purpura following FD QSNd:YAG laser treatment of epidermal pigmented lesions led us to evaluate the use of this laser in the treatment of vascular lesions. The treatment protocol was designed to assess the efficacy of the FD QSNd:YAG laser in the treatment of small cutaneous vascular lesions such as telangiectases and small angiomas. The FD QSNd:YAG laser (532 nm, 3-mm spot size, and 5-10-nanosecond pulse width) at 1-2 J/cm2 and 3-4 J/cm2 was used on two comparable cutaneous vascular lesions on the skin of each subject. Patients were treated once, with follow-up at 1-, 2-, and 6-month intervals, to examine both clinical improvement as well as potential adverse sequelae.
RESULTS: Lesions treated with the FD QSNd:YAG laser at both 1-2 J/cm2 and at 3-4 J/cm2 were improved. Statistically greater improvement was achieved when the FD QSNd:YAG laser was used at 3-4 J/cm2.
CONCLUSIONS: Clinical improvement of small cutaneous vascular lesions is possible with the FD QSNd:YAG laser.

Entities:  

Mesh:

Year:  1996        PMID: 9246165     DOI: 10.1111/j.1524-4725.1996.tb00585.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  2 in total

1.  Neodymium:YAG laser treatment of lower leg telangiectasia: a new minimally invasive approach.

Authors:  Tommaso Iannitti; Roberto Lonardi; Valentina Rottigni; Beniamino Palmieri
Journal:  Lasers Med Sci       Date:  2011-12-29       Impact factor: 3.161

2.  [Laser surgery in dermatology. Risks and chances].

Authors:  W Kimmig
Journal:  Hautarzt       Date:  2003-05-15       Impact factor: 0.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.